X-linked Adrenoleukodystrophy Clinical Trial
Official title:
Quality of Life in Female Carriers of X-linked Adrenoleukodystrophy
X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body causing damage to the central nervous system (white matter of the brain and spinal cord). The most common adult-onset X-ALD phenotype is adrenomyeloneuropathy (AMN), a slowly progressive myelopathic variant with demyelination of the long tracts in the spinal cord, clinically manifested as slowly progressive spastic paraparesis, sensory ataxia, bladder and sexual dysfunction. Although this rare disease is inherited X-linked, previous research revealed that up to 80% of heterozygous women develop AMN symptoms during their lifetime. The primary objectives of this study are 1) to assess the prevalence of symptomatic courses in female carriers of X-ALD and 2) to determine the impact of AMN symptoms on the quality of life of affected women in various areas (including everyday life, work, social network, sleep quality, sexuality, mood). Participants are asked to fill in self-report questionnaires, which are available in English, German, French, Spanish, and Italian, and are provided electronically on the online platform Leuconnect (https://www.leuconnect.com) launched by European Leukodystrophies Association (ELA) international (https://elainternational.eu/).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05911919 -
Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
|
||
Recruiting |
NCT03727555 -
Lentiviral Gene Therapy for X-ALD
|
N/A | |
Completed |
NCT02595489 -
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
|
Phase 1 | |
Completed |
NCT01594853 -
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
|
N/A | |
Completed |
NCT04687007 -
SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD)
|
N/A | |
Completed |
NCT01165060 -
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
|
N/A | |
Recruiting |
NCT05939232 -
Registry of X-linked Adrenoleukodystrophy
|
||
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Completed |
NCT03864523 -
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
|
Phase 2 | |
Recruiting |
NCT06178120 -
Disease Progression in Women With X-linked Adrenoleukodystrophy
|
||
Recruiting |
NCT03278899 -
A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
|
||
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Withdrawn |
NCT03196765 -
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01787578 -
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
|
Phase 1 | |
No longer available |
NCT02233257 -
Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy
|
N/A |